# Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

## TL;DR

This paper provides guidelines for using a specific radioactive therapy in prostate cancer patients based on recent clinical trials and expert consensus.

## Contribution

The paper offers new multidisciplinary recommendations for using [177Lu]Lu-PSMA-617 in prostate cancer diagnosis and treatment.

## Key findings

- Clinical trials like VISION, TheraP, and PSMAfore showed [177Lu]Lu-PSMA-617 has significant antitumor activity.
- The recommendations are based on current scientific evidence and multidisciplinary consensus.
- The radioligand is used for both diagnosis and treatment of PSMA-positive prostate cancer.

## Abstract

Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained significant importance to treat neuroendocrine tumors and is currently being used in prostate cancer. Various radiopharmaceuticals have emerged for diagnosing and detecting lesions showing prostate-specific membrane antigen (PSMA) positivity on the Positron emission tomography/computed tomography scan, being the most widely used labeled with [68Ga] and [18F]. Its use as therapy in prostate cancer (PC) has been assessed in the VISION, TheraP, and PSMAfore clinical trials conducted with the radioligand [177Lu]Lu-PSMA-617, demonstrating significant antitumor activity. The aim of this article is to present practical recommendations, based on current available scientific evidence and on a multidisciplinary consensus, for the diagnosis and treatment with [177Lu]Lu-PSMA-617 in patients with PC.